Amarin Corporation plc (AMRN) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - General

14/25

Growth 5 Margin 2 Expansion 1 Platform 1 Financial 5

latest quarter score

Earnings Reports

14
Ameren (AMRN) Q2 2026: International VSCEPA Demand Jumps 59%, Restructuring Delivers Leaner Model
July 29, 2026
13
Ameren (AMRN) Q1 2026: Operating Expenses Down 31% as Restructuring Delivers Margin Reset
April 29, 2026
11
Ameren (AMRN) Q4 2025: $36M Restructuring Drives 41% OPEX Cut as Partnered Model Takes Hold
February 25, 2026
11
Ameren (AMRN) Q3 2025: Operating Margin Improves 38 Points as Partnered Model Takes Hold
October 29, 2025
11
Ameren (AMRN) Q2 2025: $70M Cost Reset and Recordati Deal Reshape Global Margin Trajectory
August 05, 2025
13
Amarin (AMRN) Q1 2025: European Revenue Up 16% Sequentially Amid U.S. Generic Pressure
May 07, 2025
11
Amarin (AMRN) Q4 2024: U.S. Revenue Pressures Offset by Global Expansion and Scientific Momentum
March 12, 2025
Ameren (AMRN) Q3 2024: European Revenue Jumps $3.5M as U.S. Generic Pressures Mount
October 30, 2024
Ameren (AMRN) Q2 2024: European Net Product Revenue Climbs $2.9M as U.S. Faces Formulary Loss
July 31, 2024
Amarin (AMRN) Q1 2024: Europe In-Market Sales Surge 65% as IP Protection Extends to 2039
May 01, 2024
Ameren (AMRN) Q4 2023: Europe Product Revenue Jumps 65% as Global Expansion Drives Optionality
February 29, 2024
14
Amarin (AMRN) Q3 2023: OpEx Falls $14M as Europe Lags, U.S. Cash Engine Persists
November 01, 2023
Ameren (AMRN) Q1 2023: Operating Expenses Down 44% as Cost Discipline and Europe Focus Take Hold
May 03, 2023
Amarin (AMRN) Q4 2022: $100M Cost Cuts Drive European Launch Expansion Amid U.S. Generic Headwinds
March 01, 2023

Browse all companies